Genetic Engineering and Biotechnology News

Home Multimedia Webinars

Webinars

Emerging Trends in Fluid Transfers and Freeze-Thaw Workflows

In this GEN webinar, our expert speakers will discuss the latest trends, challenges, and innovations shaping fluid transfer and freeze-thaw workflows.

Advancing Brain Organoids from Research Models to Scalable Platforms

In this GEN webinar, our expert panelists will discuss some of the scientific and practical barriers that are facing brain organoid research and strategies for improving organoid-to-organoid and experiment-to-experiment consistency.

Lock Down the Critical Factors in Oligo and Oligo-Conjugate Characterization with Stunner and Honeybun

This GEN webinar follows oligo quantification from method development through conjugate characterization.

How Preclinical Manufacturing Can De-Risk the Path to GMP-Ready Viral Vector Programs

In this GEN webinar, Chris Nieder, an expert in viral vector programs, will examine how strategically designed preclinical manufacturing campaigns provide a practical foundation for GMP production.

Advancing Cell Therapy for Cardiovascular Disease

In TODAY’s GEN webinar, our expert speaker Joshua Michael Hare, MD, will examine how therapeutically relevant research is helping shape the development of cell therapies for cardiovascular disease.

The Next Wave of ADC Innovation: The Science Behind Dual-Payload Bioconjugates

In this GEN webinar, our expert speaker, Cindy Cheng, PhD, will explore how mechanism-driven payload pairing counters specific resistance pathways by combining orthogonal or complementary mechanisms.

Right Resin, Right Order: A Two-Step Polishing Strategy for Bispecific Antibodies

In this GEN webinar, our expert speaker, Emily Gaither, will present a systematic path from high-throughput resin screening to the selection and sequencing of two polishing steps, using emicizumab, an asymmetric IgG4 bsAb as a case study.

Is Targeted Protein Degradation the “Break” Neurology Needs?

In this GEN webinar, our expert speaker Angela M. Cacace, PhD, will discuss the increasing rationale for targeting key drivers of neurological disease with protein degraders and how this approach may enable deeper, more precise modulation of disease biology.

One Standard, Multiple Platforms: ICH Q2(R2) Qualification of Host Cell Protein Analysis by LC–MS/MS

In this GEN webinar, USP and Alphalyse present the work qualifying beta-lactoglobulin (LACB) as a cross-platform standard for LC-MS/MS HCP analysis.

Advancing Microbial-Derived Biologics from Scale-Up to Commercial Production

In this GEN webinar, our expert speaker, Sam Zhang, PhD, will discuss emerging trends and capacity needs across the global late-stage microbial pipeline and CDMO landscape.

Embedding Regulatory Strategy in Cell and Gene Therapy Development

In this GEN webinar, experts from Rose BioSolutions, a CDMO and Cell Solutions organization formed from Charles River Laboratories’ businesses, will discuss how integrating regulatory strategy at the earliest stages of development can reduce overall risk and improve program outcomes.

Built Without Bacteria: Bringing Cell-Free Synthesis to the Bench

In this GEN webinar, speakers from Flock Bio and Ribbon Bio will explore how bench-based, cell-free DNA production can complement expertise in custom DNA design and manufacturing.

In Vivo Protein Generation Using Nanoparticle Delivery: Emerging Platforms and CMC Strategies

In this GEN webinar, our expert speaker, Tao (Tony) Li, PhD, will discuss nanoparticle delivery opportunities beyond oncology and infectious disease, compare emerging nanocarrier platforms, and examine important CMC considerations critical for progressing from research through IND.

When Process Design Fails: 5 Common Planning Gaps That Create Downstream Purification Bottlenecks

In this GEN webinar, our speakers will examine five common planning gaps that can contribute to bottlenecks, including single-source material dependency, raw material pack size selection, sensitive buffer designs, and single-use systems designed without realistic failure modes.